Tetracosactide depot - Slan Medicinal Holdings

Drug Profile

Tetracosactide depot - Slan Medicinal Holdings

Alternative Names: Cosyntropin depot - Slán Medicinal Holdings; Synthetic ACTH Depot - Slán Medicinal Holdings

Latest Information Update: 17 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Mallinckrodt Inc.
  • Developer Depomed; Mallinckrodt Inc.; Slan Medicinal Holdings
  • Class Anti-inflammatories; Corticosteroids; Immunotherapies; Melanocortins; Peptides
  • Mechanism of Action Melanocortin receptor agonists; Steroid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Infantile spasms
  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Adrenal gland disorders; Infantile spasms

Most Recent Events

  • 10 May 2018 Clinical trials in Infantile spasms in USA (Parenteral)
  • 27 Feb 2018 Depomed and West Therapeutic Development plans to launch tetracosactide depot in the late 2019 or early 2020
  • 07 Nov 2017 Depomed and West Therapeutic Development (Slan Medicinal Holdings) plan a clinical trial for Infantile spasms in USA in early 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top